{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:48:32Z","timestamp":1767649712269,"version":"build-2065373602"},"reference-count":98,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Objective: This survey aimed to explore knowledge and experience on novel psychoactive substances (NPS) of healthcare professionals (HCPs). The study also aimed to assess how HCPs would like to improve their knowledge of NPS. Methods: Seventy paper questionnaires were disseminated in 2017 within continuing education events to pharmacists, nurses and general practitioners (GPs). Additionally, 127 online surveys were completed using the Qualtrics platform by other HCPs and mental health nurses in six United Kingdom (UK) independent mental health hospitals long-stay in-patient rehabilitation services. Two educational sessions involving pharmacists and GPs were also held in late 2017 and mid-2018. Knowledge of NPS by HCPs was evaluated prior to the start of the educational events. Evaluation forms were handed out post-sessions to garner feedback, especially on areas for improvement for future sessions. Statistical analysis of data was undertaken using SPSS (V.25). Results: Most HCPs reported only \u2018basic\u2019 to \u2018intermediate\u2019 NPS knowledge. Substance misuse service staff felt more informed, were more often consulted and had greater confidence regarding NPS compared to hospital and primary care professionals. A negative association was found between the age of the HCP and knowledge of NPS. Most participants expressed a need for regular training and updates as insufficient NPS-related information is currently received. Conclusions: An improvement within the self-reported knowledge of HCPs on NPS is evident in comparison to previous studies. Continued education of HCPs on NPS is fundamental for the provision of improved harm reduction services, which can enhance overall care for NPS service users.<\/jats:p>","DOI":"10.3390\/brainsci10030142","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T13:06:23Z","timestamp":1583240783000},"page":"142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances"],"prefix":"10.3390","volume":"10","author":[{"given":"Camille","family":"Ramos","sequence":"first","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-0660","authenticated-orcid":false,"given":"Amira","family":"Guirguis","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"},{"name":"Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea SA2 8PP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-5411","authenticated-orcid":false,"given":"Nigel","family":"Smeeton","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4252-2822","authenticated-orcid":false,"given":"Hadar","family":"Zaman","sequence":"additional","affiliation":[{"name":"Bradford School of Pharmacy &amp; Medical Sciences, Faculty of Life Sciences, University of Bradford, Horton Road, Bradford BD7 1DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Marie","family":"Felice","sequence":"additional","affiliation":[{"name":"CGL, St Martins House, 14 The Common, Hatfield AL10 0UR, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Bancroft","sequence":"additional","affiliation":[{"name":"London North West Local Pharmacy Forum (LNWLPF) of the Royal Pharmaceutical Society, Pinner, Middlesex HA5 3EP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind","family":"Gittins","sequence":"additional","affiliation":[{"name":"Humankind, Inspiration House, Unit 22 Bowburn North Industrial Estate, Durham DH6 5PF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gill","family":"Hawksworth","sequence":"additional","affiliation":[{"name":"Royal Pharmaceutical Society, 66-68 E Smithfield, Whitechapel, London E1W 1AW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-817X","authenticated-orcid":false,"given":"John Martin","family":"Corkery","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4178-5401","authenticated-orcid":false,"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"ref_1","unstructured":"UNODC (2019, September 19). The Challenge of New Psychoactive Substances, Available online: https:\/\/www.unodc.org\/documents\/scientific\/NPS_2013_SMART.pdf."},{"key":"ref_2","unstructured":"EMCDDA-Europol The state of the drugs problem in Europe\u2014Annual report 2012, Publications Office of the European Union. Available online: http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_190854_EN_TDAC12001ENC_.pdf."},{"key":"ref_3","unstructured":"ACMD (2019, September 19). Consideration of the Novel Psychoactive Substances (\u2018Legal Highs\u2019), Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/119139\/acmdnps2011.pdf."},{"key":"ref_4","unstructured":"(2019, September 19). Psychoactive Substances Act 2016, Available online: https:\/\/www.legislation.gov.uk\/ukpga\/2016\/2\/pdfs\/ukpga_20160002_en.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Schifano, F. (2018). Recent Changes in Drug Abuse Scenarios: The New\/Novel Psychoactive Substances (NPS) Phenomenon. Brain Sci., 8.","DOI":"10.3390\/brainsci8120221"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Corkery, J., Orsolini, L., Papanti, D., and Schifano, F. (2018). Novel psychoactive substances (NPS) and recent scenarios: Epidemiological, anthropological and clinical pharmacological issues. Light in Forensic Science: Issues and Applications, Royal Society of Chemistry. Chapter 8.","DOI":"10.1039\/9781788010344-00207"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(14)60822-9","article-title":"Legal highs: A problem of definitions?","volume":"383","author":"Goodair","year":"2014","journal-title":"Lett. Lancet"},{"key":"ref_8","unstructured":"Home Office (2020, February 26). Review of the Psychoactive Substances Act 2016, Available online: https:\/\/www.gov.uk\/government\/publications\/review-of-the-psychoactive-substances-act-2016."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Deligianni, E., Daniel, O.J., Corkery, J.M., Schifano, F., and Lione, L. (2019). Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of Novel Psychoactive Substances. Br. J. Clin. Pharmacol.","DOI":"10.1111\/bcp.14123"},{"key":"ref_10","unstructured":"UNODC (2019, September 19). UNODC World Drug Report, Available online: https:\/\/www.unodc.org\/LSS\/announcement\/Details\/fa879924-6bdf-4ba2-a8eb-a87185d26439."},{"key":"ref_11","unstructured":"UNODC (2019, September 19). UNODC-SMART: Almost 900 NPS Reported to UNODC from 119 countries and territories, Available online: https:\/\/www.unodc.org\/LSS\/Announcement\/Details\/eff8dc38-7ab0-42b0-8cd9-753b89953fcc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/bjaed\/mkw068","article-title":"Novel psychoactive substances: A practical approach to dealing with toxicity from legal highs","volume":"17","author":"Dignam","year":"2017","journal-title":"BJA Educ."},{"key":"ref_13","unstructured":"Winstock, A., Barratt, M., Maier, L., Aldridge, A., Zhuparis, A., Davies, E., and Ferris, J. (2020, February 26). Global Drug Survey (GDS) 2019 Key Findings Report. Available online: https:\/\/www.globaldrugsurvey.com\/gds-2019\/."},{"key":"ref_14","unstructured":"ONS (2019, September 19). Deaths related to drug poisoning in England and Wales: 2018 registrations, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2018registrations\/pdf."},{"key":"ref_15","unstructured":"NRS (2019, September 19). Drug-related Deaths in Scotland in 2018, Available online: https:\/\/www.nrscotland.gov.uk\/files\/\/statistics\/drug-related-deaths\/2018\/drug-related-deaths-18-pub.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15563650.2018.1494277","article-title":"Change in the new psychoactive substances associated with Emergency Department acute toxicity presentations associated with the introduction of the UK 2016 Psychoactive Substances Act","volume":"57","author":"Webb","year":"2019","journal-title":"Clin. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0036933018760761","article-title":"A prospective observational study of emergency department presentations following novel psychoactive substance use","volume":"63","author":"Henshall","year":"2018","journal-title":"Scott. Med. J."},{"key":"ref_18","unstructured":"EMCDDA (2019, September 19). Fentanils and Synthetic Cannabinoids: Driving Greater Complexity into the Drug Situation, Available online: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/8870\/2018-2489-td0118414enn.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1399-6576.1982.tb01765.x","article-title":"Potent, new analgesics, tailor-made for different purposes","volume":"26","author":"Janssen","year":"1982","journal-title":"Acta Anaesthesiol. Scand."},{"key":"ref_20","unstructured":"WHO (2017). Carfentanil Critical Review Report Agenda Item 4.8 Expert Committee, World Health Organisation. Available online: https:\/\/www.who.int\/medicines\/access\/controlled-substances\/Critical_Review_Carfentanil.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuropharm.2017.08.016","article-title":"Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace","volume":"134","author":"Baumann","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00046","article-title":"Assessing the 2004\u20132018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems","volume":"10","author":"Schifano","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/hup.2586","article-title":"Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza","volume":"32","author":"Martinotti","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2606","DOI":"10.1002\/hup.2606","article-title":"The risk of violence associated with novel psychoactive substance misuse in patients presenting to acute mental health services","volume":"32","author":"Shafi","year":"2017","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"ref_25","unstructured":"EMCDDA (2019, September 19). European Drug Report Trends and Developments, Available online: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/8585\/20181816_TDAT18001ENN_PDF.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ams2.182","article-title":"Clinical and toxicological findings of acute intoxication with synthetic cannabinoids and cathinones","volume":"3","author":"Fujita","year":"2016","journal-title":"Acute Med. Surg."},{"key":"ref_27","unstructured":"Abdulrahim, D., Bowden-Jones, O., and On behalf of the NEPTUNE Group (2015). Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances, The Health Foundation. Available online: http:\/\/neptune-clinical-guidance.co.uk\/wp-content\/uploads\/2015\/03\/NEPTUNE-Guidance-March-2015.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/sextrans-2015-052052","article-title":"Illicit drug use in sexual settings (\u2018chemsex\u2019) and HIV\/STI transmission risk behaviour among gay men in South London: Findings from a qualitative study","volume":"91","author":"Bourne","year":"2015","journal-title":"Sex. Transm. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.drugpo.2015.07.013","article-title":"\u201cChemsex\u201d and harm reduction need among gay men in South London","volume":"26","author":"Bourne","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency\u2019s \u2018Suspected Adverse Drug Reactions\u2019 Database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40261-017-0616-y","article-title":"Intentional Drug Overdose Involving Pregabalin and Gabapentin: Findings from the National Self-Harm Registry Ireland, 2007\u20132015","volume":"38","author":"Daly","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the Effect of Buprenorphine\/Naloxone With Gabapentin or Quetiapine","volume":"171","author":"Reeves","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"ref_33","unstructured":"EMCDDA (2020, February 26). The misuse of benzodiazepines among high-risk opioid users in Europe, Available online: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2733\/Misuse%20of%20benzos_POD2015.pdf."},{"key":"ref_34","unstructured":"Johnson, C.F., Barnsdale, L.R., and McAuley, A. (2019, September 19). Investigating the role of benzodiazepines in drug-related mortality: A systematic review undertaken on behalf of The Scottish National Forum on Drug-Related Deaths. Available online: https:\/\/dspace.stir.ac.uk\/handle\/1893\/23220#.XCtFKlz7TtQ."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/dta.2211","article-title":"The emergence of new psychoactive substance (NPS) benzodiazepines: A review","volume":"10","author":"Manchester","year":"2018","journal-title":"Drug Test. Anal."},{"key":"ref_36","unstructured":"NRS (2019, September 19). Drug-related deaths in Scotland 2016, Available online: https:\/\/www.nrscotland.gov.uk\/files\/\/statistics\/drug-related-deaths\/drd2016\/drug-related-deaths-16-pub.pdf."},{"key":"ref_37","unstructured":"NRS (2019, September 19). Drug-related deaths in Scotland in 2017, Available online: https:\/\/www.nrscotland.gov.uk\/files\/statistics\/drug-related-deaths\/17\/drug-related-deaths-17-pub.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.drugpo.2016.11.003","article-title":"Health and Social Care workers\u2019 perceptions of NPS use in Northern Ireland","volume":"40","author":"Campbell","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gittins, R., Guirguis, A., Schifano, F., and Maidment, I. (2018). Exploration of the use of new psychoactive substances by individuals in treatment for substance misuse in the UK. Brain Sci., 8.","DOI":"10.3390\/brainsci8040058"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1108\/DAT-03-2015-0012","article-title":"Survey of knowledge of legal highs (novel psychoactive substances) amongst London pharmacists","volume":"15","author":"Guirguis","year":"2015","journal-title":"Drugs Alcohol Today"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1108\/ADD-07-2017-0008","article-title":"Novel psychoactive substance use by mental health service consumers: An online survey of inpatient health professionals\u2019 views and experiences","volume":"11","author":"Hughes","year":"2018","journal-title":"Adv. Dual Diagn."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1108\/DAT-03-2017-0011","article-title":"Psychiatrists\u2019 knowledge of novel psychoactive substances","volume":"17","author":"Owie","year":"2017","journal-title":"Drugs Alcohol Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/qjmed\/hcv208","article-title":"Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational drugs","volume":"109","author":"Wood","year":"2016","journal-title":"QJM"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hup.2300","article-title":"Novel psychoactive substances as a novel challenge for health professionals: Results from an Italian survey","volume":"28","author":"Simonato","year":"2013","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"ref_45","first-page":"25","article-title":"Novel Drugs, Novel Solutions: Exploring the potential of technological tools for prevention of drug abuse","volume":"1","author":"Corazza","year":"2011","journal-title":"Ital. J. Addict."},{"key":"ref_46","unstructured":"ReDNet Research Group (2019, September 19). Le nuove potenzialit\u00e0 della prevenzione digitale in materia di nuove droghe\u2014Research Database\u2014University of Hertfordshire. Dipendenze Patologiche. Available online: http:\/\/researchprofiles.herts.ac.uk\/portal\/en\/publications\/le-nuove-potenzialita-della-prevenzione-digitale-in-materia-di-nuove-droghe(e4511105-5c1d-479f-b9ea-e6bea4e489c7)\/export.html."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1136\/bmj.i6814","article-title":"Novel psychoactive substances: Identifying and managing acute and chronic harmful use","volume":"356","author":"Tracy","year":"2017","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1136\/bmj.i6848","article-title":"Novel psychoactive substances: Types, mechanisms of action, and effects","volume":"356","author":"Tracy","year":"2017","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"ref_49","unstructured":"EMCDDA-Europol (2019, September 19). EMCDDA\u2013Europol 2017 Annual Report on the implementation of Council Decision 2005\/387\/JHA, Available online: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/9282\/20183924_TDAN18001ENN_PDF.pdf."},{"key":"ref_50","unstructured":"Macleod, S. (2019, September 19). Likert Scale. Simply Psychology. Available online: https:\/\/www.simplypsychology.org\/likert-scale.html."},{"key":"ref_51","unstructured":"Guirguis, A., Hawksworth, G., Bond, C., Lawrence, J., and Martini, L.G. (2018). New Psychoactive Substances: A Guide for Pharmacists, Royal Pharmaceutical Society. Available online: https:\/\/www.rpharms.com\/Portals\/0\/RPS%20document%20library\/Open%20access\/Science\/RPS%20NPS%20Fact%20sheet.pdf?ver=2018-06-18-141822-160."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.encep.2015.09.002","article-title":"Usage de cathinones \u00e0 Paris","volume":"42","author":"Batisse","year":"2016","journal-title":"L\u2019Enc\u00e9phale"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/109493103322278790","article-title":"Importance of cyberspace for the assessment of the drug abuse market: Preliminary results from the Psychonaut 2002 project","volume":"6","author":"Schifano","year":"2003","journal-title":"Cyberpsychology Behav."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/09687637.2017.1417352","article-title":"New psychoactive substances: New service provider challenges","volume":"25","author":"Ralphs","year":"2018","journal-title":"Drugs Educ. Prev. Policy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/ijnp\/pyz007","article-title":"An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions","volume":"22","author":"Schifano","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","article-title":"Mechanisms of fatal opioid overdose","volume":"94","author":"White","year":"1999","journal-title":"Addiction (Abingdon Engl.)"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Schifano, F., Chiappini, S., Corkery, J.M., and Guirguis, A. (2018). Abuse of prescription drugs in the context of novel psychoactive substances (NPS): A systematic review. Brain Sci., 8.","DOI":"10.3390\/brainsci8040073"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/add.14412","article-title":"Rising pregabalin use and misuse in Australia: Trends in utilization and intentional poisonings","volume":"114","author":"Cairns","year":"2019","journal-title":"Addiction"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/cns.13115","article-title":"Pregabalin: A range of misuse-related unanswered questions","volume":"25","author":"Schifano","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"ref_60","unstructured":"Winstock, A., Barratt, M., Maier, L., Aldridge, A., Zhuparis, A., Davies, E., and Ferris, J. (2020, February 26). Global Drug Survey (GDS) 2018 Key Findings Report. Available online: https:\/\/www.globaldrugsurvey.com\/gds-2018\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.forsciint.2017.11.036","article-title":"Multiple fatalities in the North of England associated with synthetic fentanyl analogue exposure: Detection and quantitation a case series from early 2017","volume":"282","author":"Hikin","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"ref_62","unstructured":"Abdulrahim, D., and Bowden-Jones, O. (2018). The Misuse of Synthetic Opioids: Harms and Clinical Management of Fentanyl, Fentanyl Analogues and Other Novel Synthetic Opioids Information for Clinicians, The Health Foundation. Available online: http:\/\/neptune-clinical-guidance.co.uk\/wp-content\/uploads\/2018\/03\/The-misuse-of-synthetic-opioids.pdf."},{"key":"ref_63","unstructured":"Bourne, A., Reid, D., Hickson, F., Torres, S., and Weatherburn, R.P. (2019, September 19). The Chemsex Study: Drug Use in Sexual Settings Among Gay and Bisexual Men in Lambeth, Southwark and Lewisham, Available online: https:\/\/www.lambeth.gov.uk\/sites\/default\/files\/ssh-chemsex-study-final-main-report.pdf."},{"key":"ref_64","unstructured":"Keogh, P., Reid, D., Bourne, A., Weatherburn, P., Hickson, F., Jessup, K., and Hammond, G. (2009). Wasted Opportunities: Problematic Alcohol and Drug Use among Gay Men and Bisexual Men, Sigma Research, London School of Hygiene & Tropical Medicine. Available online: http:\/\/researchonline.lshtm.ac.uk\/1408\/."},{"key":"ref_65","unstructured":"Sample, I. (2019, September 19). \u2018Superman\u2019 pill deaths spark calls for dangerous-drugs alert system. Available online: https:\/\/www.theguardian.com\/society\/2015\/jan\/16\/superman-pill-deaths-dangerous-drugs-alert-system."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Guirguis, A., Corkery, J.M., Stair, J.L., Zloh, M., Kirton, S.B., and Schifano, F. (2017). Intended and unintended use of cathinone mixtures. J. Hum. Psychopharmacol. Clin. Exp., 32.","DOI":"10.1002\/hup.2598"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/10826080903443628","article-title":"Legal Highs on the Internet","volume":"45","author":"Hillebrand","year":"2010","journal-title":"Subst. Use Misuse"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00216-012-6122-4","article-title":"Analysis of synthetic cannabinoids in \u201cspice-like\u201d herbal highs: Snapshot of the German market in summer 2011","volume":"404","author":"Simolka","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_69","unstructured":"Guirguis, A., Hawksworth, G., Bond, C., Lawrence, J.M., and Martini, L.G. (2018). New psychoactive substances. Quick Reference Guides, Royal Pharmaceutical Society. Available online: https:\/\/www.rpharms.com\/resources\/quick-reference-guides\/new-psychoactive-substances."},{"key":"ref_70","unstructured":"World Health Organization (2016). Technical Series on Safer Primary Care. Education and Training: Technical Series on Safer Primary Care, World Health Organization."},{"key":"ref_71","unstructured":"EMCDDA (2019, September 19). Health Responses to New Psychoactive Substances, Available online: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2812\/TD0216555ENN.pdf."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1093\/pubmed\/fdy016","article-title":"The public health evidence-base on novel psychoactive substance use: Scoping review with narrative synthesis of selected bodies of evidence","volume":"40","author":"Meader","year":"2018","journal-title":"J. Public Health (Oxf. Engl.)"},{"key":"ref_73","unstructured":"UNODC (2019, September 19). Market Analysis of Synthetic Drugs. Amphetamine-Type Stimulants, New Psychoactive Substances. World Drug Report 2017, Available online: http:\/\/www.unodc.org\/documents\/scientific\/Booklet_4_Market_Analysis_of_Synthetic_Drugs_ATS_NPS.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/ijpp.12313","article-title":"New psychoactive substances: A public health issue","volume":"25","author":"Guirguis","year":"2017","journal-title":"Int. J. Pharm. Pract."},{"key":"ref_75","unstructured":"EMCDDA (2019, September 19). Health and Social Responses to Drug Problems. A European Guide, Available online: https:\/\/publications.europa.eu\/en\/publication-detail\/-\/publication\/d8574d27-ae31-11e7-837e-01aa75ed71a1\/language-en."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(11)61674-7","article-title":"Drug policy and the public good: Evidence for effective interventions","volume":"379","author":"Strang","year":"2012","journal-title":"Lancet"},{"key":"ref_77","unstructured":"PHE (2019, September 19). New Psychoactive Substances (A toolkit for Substance Misuse Commissioners), Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/669429\/nps-a-toolkit-for-substance-misuse-commissioners.pdf."},{"key":"ref_78","unstructured":"Tang, W. (2017). New Psychoactive Substances (NPS). Medicines, Ethics and Practice. The Professional Guide for Pharmacists, Royal Pharmaceutical Society. [41st ed.]."},{"key":"ref_79","unstructured":"Royal Pharmaceutical Society (2019, September 19). Medicines, Ethics and Practice (MEP) 43. Available online: https:\/\/www.rpharms.com\/resources\/publications\/medicines-ethics-and-practice-mep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00365513.2013.793817","article-title":"Identification of novel psychoactive drug use in Sweden based on laboratory analysis\u2014Initial experiences from the STRIDA project","volume":"73","author":"Helander","year":"2013","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_81","first-page":"7923","article-title":"First Home Office-licensed street drug-testing clinic opens","volume":"302","author":"Burns","year":"2019","journal-title":"Pharm. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fpsyt.2018.00135","article-title":"Candyflipping and Other Combinations: Identifying Drug-Drug Combinations from an Online Forum","volume":"9","author":"Chary","year":"2018","journal-title":"Front. Psychiatry"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jpba.2014.12.033","article-title":"1H, 13C, 15N HMBC, and 19F NMR spectroscopic characterisation of seized flephedrone, cut with benzocaine","volume":"107","author":"Alotaibi","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.forsciint.2011.08.011","article-title":"The analysis of substituted cathinones. Part 3. Synthesis and characterisation of 2,3-methylenedioxy substituted cathinones","volume":"216","author":"Kavanagh","year":"2012","journal-title":"Forensic Sci. Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/dta.1365","article-title":"Prevalence and co-existence of active components of \u201clegal highs.\u201d","volume":"5","author":"Zuba","year":"2013","journal-title":"Drug Test. Anal"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.toxlet.2014.06.012","article-title":"Understanding the risks associated with the use of new psychoactive substances (NPS): High variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products","volume":"229","author":"Zamengo","year":"2014","journal-title":"Toxicol. Lett."},{"key":"ref_87","first-page":"1116","article-title":"Novel psychoactive substances: Understanding the new illegal drug market","volume":"10","author":"Guirguis","year":"2018","journal-title":"Clin. Pharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0204443","article-title":"Is there such a thing as a \u201clope\u201d dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports","volume":"13","author":"Schifano","year":"2018","journal-title":"PLoS ONE"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/17512433.2016.1178571","article-title":"The consequences of drug misuse on post-marketing surveillance","volume":"9","author":"Schifano","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13012-017-0670-0","article-title":"The effects of care bundles on patient outcomes: A systematic review and meta-analysis","volume":"12","author":"Gray","year":"2017","journal-title":"Implement. Sci."},{"key":"ref_91","unstructured":"Abdulrahim, D., and Bowden-Jones, O. (2016). Harms of Synthetic Cannabinoid Receptor Agonists (SCRAs) and Their Management, The Health Foundation. Available online: http:\/\/neptune-clinical-guidance.co.uk\/wp-content\/uploads\/2016\/07\/Synthetic-Cannabinoid-Receptor-Agonists.pdf."},{"key":"ref_92","unstructured":"Adley, M. (2019, April 16). The Drugs Wheel. Version 2.0.6. Available online: http:\/\/www.thedrugswheel.com\/."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"734749","DOI":"10.1155\/2014\/734749","article-title":"25C-NBOMe: Preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug","volume":"2014","author":"Bersani","year":"2014","journal-title":"Biomed Res. Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"815424","DOI":"10.1155\/2014\/815424","article-title":"Novel psychoactive substances in young adults with and without psychiatric comorbidities","volume":"2014","author":"Martinotti","year":"2014","journal-title":"Biomed Res. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"617546","DOI":"10.1155\/2014\/617546","article-title":"Substance Use in the Club Scene of Rome: A Pilot Study","volume":"2014","author":"Vento","year":"2014","journal-title":"Biomed Res. Int."},{"key":"ref_96","unstructured":"Independent Expert Working Group (2019, September 19). Drug Misuse and Dependence: UK Guidelines on Clinical Management, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/673978\/clinical_guidelines_2017.pdf."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fphar.2018.00239","article-title":"Is there a potential of misuse for venlafaxine and bupropion?","volume":"9","author":"Schifano","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11648\/j.ajtas.20160501.11","article-title":"Comparison of Convenience Sampling and Purposive Sampling","volume":"5","author":"Etikan","year":"2016","journal-title":"Am. J. Theor. Appl. Stat."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/10\/3\/142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:03:24Z","timestamp":1760173404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/10\/3\/142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":98,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["brainsci10030142"],"URL":"https:\/\/doi.org\/10.3390\/brainsci10030142","relation":{},"ISSN":["2076-3425"],"issn-type":[{"type":"electronic","value":"2076-3425"}],"subject":[],"published":{"date-parts":[[2020,3,2]]}}}